BLUE JET HEALTHCARE LIMITED
REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705
T : 022- 41840550 / 40037603 | F : +91 22 27814204
E : sales@bluejethealthcare.com | CIN NO. : U99999MH1968PLC014154

November 5, 2026

To,

BSE Limited Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	**National Stock Exchange of India Limited** "Exchange Plaza" Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET

Sub: Analysts/Investors Presentation on Financial Results for the quarter ended September 30, 2026.

Dear Sir / Ma'am,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Analysts/Investors Presentation on the Financial Results for the quarter ended September 30, 2026.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Blue Jet Healthcare Limited**

Sweta Poddar
Digitally signed by Sweta Poddar
Date: 2026.11.05 16:03:38 +05'30'

Sweta Poddar
Company Secretary & Compliance Officer

BLUE JET HEALTHCARE

Investor Presentation

Q2 & H1 FY27



Disclaimer

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Blue Jet Healthcare Ltd.

BLUE JET HEALTHCARE

Table of **Content**



1 Q2 & H1 FY27 Financials

2 Company at a Glance

3 Contrast Media Intermediates

4 High Intensity Sweeteners

5 Pharma Intermediates & API

6 R&D Capabilities

7 Growth Strategy

8 Management and Board of Directors




1


Q2 & H1 FY27 Financials


Q2 & H1 FY27 Earnings Highlights


Business Updates

- ✓ **This quarter we clocked Highest Quarterly Sales at Rs 3,757mn.**
- ✓ **The R&D centre at Hyderabad facilities are operational now with 40 resources onboarded & activity started.**
- ✓ **The Company have successfully delivered & validated a new Contrast Media Intermediate to an innovator.**
- ✓ **Company have successfully developed Amino Acid Derivatives for Peptide Fragments and the same would be commercialized / shipped during Q4 FY27.**









Quarterly Revenue Growth

+28%
QoQ

Half Yearly Revenue Growth

+29%
YoY



Q2 FY27 vs Q1 FY27 (QoQ) Earnings Highlights

Financial Highlights

- ✓ **Revenue from Operations** in Q2 September 26 was Rs 3,757mn – Highest Quarterly Sales reported, EBITDA Rs 1,188mn (32% Margin) and PAT Rs 1,025mn (27% Margin)
- ✓ **Revenue from Operations** in Q1 June 26 was Rs 2,931mn, EBITDA Rs 981mn (33% Margin) and PAT Rs 783mn (27% Margin)
- ✓ **QoQ comparison:** Revenue from operations increased by 28%, EBITDA increased by 21% [Rs 207mn] and PAT increased by 31% [Rs 242mn] during Q2 September 26.
- ✓ **The increase in Revenue from Operations** during current quarter is due to strong growth in PI & API category (52%) as well Contrast Media (25%)
- ✓ **Other Income** increased by Rs. 110mn (72%) during Q2 September 26.



Q2 FY27 vs Q2 FY26 (YoY) Earnings Highlights

Financial Highlights

- ✓ **Revenue from Operations** in **Q2 September 26** was **Rs 3,757mn mn, EBITDA Rs 1,188mn (32% Margin)** and **PAT Rs 1,025mn (27% Margin)**
- ✓ **Revenue from Operation** in **Q2 September 25** was **Rs 1,655mn, EBITDA Rs 549mn (33% Margin)** and **PAT Rs 521mn (32 % Margin)**
- ✓ **YoY comparison, Revenue from operations increased** by **127%, EBITDA increased** by **116% [Rs 639mn]** and **PAT increased** by **97% [Rs.504mn] during Q2 September 26.**
- ✓ **The increase** in **revenue from operations during Q2 September 26 was** due to **higher sales in PI & API Category (322%)** as well as **Contrast Media (80%)**



H1 FY27 vs H1 FY26 Earnings Highlights

Financial Highlights


- ✓ **Revenue from Operation: H1 FY27 Revenue from Operation** was **Rs 6,689mn, EBITDA Rs 2,168mn (32% Margin)** and **PAT Rs 1,808mn (27% Margin).**
- ✓ **Revenue from Operation : H1 FY26 Revenue from Operations** was **Rs 5,202mn, EBITDA Rs 1,759mn (34% Margin)** and **PAT Rs 1,433mn (28% Margin)**
- ✓ **YoY comparison: Revenue from operations increase** by **29%, EBITDA increased** by **23% and PAT increased** by **26% during H1 FY27**
- ✓ **Other income: Other income increased** in **H1 FY27** by **27% [Rs 414mn] as compared to [Rs 325mn] mainly** due to **higher net foreign exchange gain .**




Q2 FY27 Vs Q1 FY27 Financial Performance – Key Metrics

Revenue from Operations** – Growth Trends


(₹ Mn)




EBITDA Profile



PAT Profile






- *Others include spent oils and industrial mix solvents and R&D services .
- **Excludes Other Operating Revenue.


Q2 FY27 Vs Q2 FY26 Financial Performance – Key Metrics

Revenue from Operations** – Growth Trends


(₹ Mn)




EBITDA Profile



PAT Profile






- *Others include spent oils and industrial mix solvents and R&D services .
- **Excludes Other Operating Revenue.


H1 FY27 Vs H1 FY26 Financial Performance – Key Metrics

Revenue from Operations** – Growth Trends


(₹ Mn)




EBITDA Profile



PAT Profile





- *Others include spent oils and industrial mix solvents and R&D services .
- **Excludes Other Operating Revenue.


Profit and Loss Statement

Particulars (Rs. Mn)	Q2 FY27	Q1 FY27	QoQ	Q2 FY26	YoY	H1 FY27	H1 FY26	YoY
Revenue from Operations	**3,757**	**2,931**	**28.2%**	**1,655**	**127.1%**	**6,689**	**5,202**	**28.6%**
Cost Of Goods Sold	1,933	1,371		579		3,304	2,408	
Gross Profit	**1,824**	**1,560**	**16.9%**	**1,076**	**69.5%**	**3,384**	**2,795**	**21.1%**
Gross Margin	*48.5%*	*53.2%*		*65.0%*		*50.6%*	*53.7%*	
Employee benefits expenses	204	201		186		405	360	
Other expenses	433	378		341		811	676	
Total Expenses	2,570	1,950		1,105		4,520	3,443	
EBITDA	**1,188**	**981**	**21.1%**	**549**	**116.1%**	**2,168**	**1,759**	**23.2%**
EBITDA Margin	*31.6%*	*33.5%*		*33.2%*		*32.4%*	*33.8%*	
Depreciation and amortization	69	67		59		136	116	
PBIT	**1,380**	**1,066**	**29.5%**	**734**	**88.2%**	**2,446**	**1,969**	**24.2%**
Finance costs	6	7		46		13	53	
Other Income	262	152		243		414	325	
PBT	**1,374**	**1,059**	**29.7%**	**687**	**99.9%**	**2,433**	**1,916**	**27.0%**
Tax Expense	349	277		166		626	483	
PAT	**1,025**	**783**	**31.0%**	**521**	**96.6%**	**1,808**	**1,433**	**26.1%**
PAT Margin	*27.3%*	*26.7%*		*31.5%*		*27.0%*	*27.5%*	


Financial Performance over the years – Key Metrics

Revenue from Operations** – Growth Trends


(₹ Mn)



EBITDA Profile



PAT Profile



- *Others include spent oils, Industrial mix solvents and R&D
- **Excludes Other Operating Revenue

Financials for the last six years

Summary Statement of Profit and Loss


Particulars (₹ Mn)	FY22	FY23	FY24	FY25	FY26	H1 FY27
Revenue from Operations	6,835	7,210	7,116	10,300	9,473	6,689
Other Income	194	240	289	463	687	414
Total Revenue	**7,029**	**7,449**	**7,404**	**10,762**	**10,160**	**7103**
Cost of Materials consumed	2,875	3,360	3,144	4,612	4,358	3,304
Employee benefits expenses	330	419	532	610	735	405
Finance costs	33	14	2	1	62	13
Depreciation and amortization	221	251	281	178	240	136
Other expenses	1,137	1,240	1,148	1,300	1,439	811
Total Expenses	**4,597**	**5,283**	**5,106**	**6,701**	**6,834**	**4,668**
Exceptional Items	-	-	(97)	-	-	-
PBT	**2,432**	**2,166**	**2,200**	**4,061**	**3,325**	**2,433**
Tax Expense	616	566	563	1,009	847	626
PAT	**1,816**	**1,600**	**1,637**	**3,052**	**2,478**	**1,808**

Summary Statement of Assets and Liabilities

Particulars (₹ Mn)	FY22	FY23	FY24	FY25	FY26	H1 FY27
I. Assets						
Property, plant and equipment	1,185	1,282	1,491	2,596	2,529	2,679
Other non-current assets	466	688	2,041	1,519	4,312	5,201
Total non-current assets	**1,651**	**1,970**	**3,532**	**4,116**	**6,841**	**7,879**
Inventories	1,050	1,257	1,298	2,639	1,874	2,513
Trade receivables	2,274	2,394	1,769	3,495	3,390	4,447
Investments (Current)	938	1,893	2,355	1,867	2,267	6,046
Cash and cash equivalents	754	654	410	330	609	767
Other current assets	467	453	1,224	1,728	1,430	4,187
Total current assets	**5,483**	**6,651**	**7,056**	**10,059**	**9,570**	**17,959**
Total assets	**7.134**	**8.621**	**10,588**	**14,175**	**16,412**	**25,839**
II. Equity and liabilities						
Total equity	**5,215**	**6,815**	**8,452**	**11,331**	**13,599**	**22,986**
Borrowings	-	-	-	-	-	-
Other non-current liabilities	173	67	77	285	538	526
Total non-current liabilities	**173**	**67**	**77**	**285**	**538**	**526**
Current borrowings	-	-	-	-	-	-
Trade payables	565	538	303	891	569	476
Other current liabilities	1,180	1,201	1,757	1,669	1,706	1,850
Total current liabilities	**1,745**	**1,739**	**2,060**	**2,559**	**2,275**	**2,327**
Total liabilities	**1,918**	**1,806**	**2,136**	**2,844**	**2,813**	**2,853**
Total equity and liabilities	**7,134**	**8,621**	**10,588**	**14,175**	**16,412**	**25,839**

Shareholder Information

Shareholding as on 30th September 2026



Share Information as on 30th September 2026

NSE Ticker	BLUEJET
BSE Ticker	544009
Market Cap (₹ Cr) (BSE)	10,198
% free-float	26.9%
Free-float market cap (₹ Cr)	2,739
Cash & Cash Equivalents + Treasury Investment (₹ Mn) (As on 30th September 2026)	4,946
Shares Outstanding	18,92,75,701
3M ADTV (Shares)*	8,69,156
3M ADTV (INR Cr)*	51.3
Industry	Pharmaceuticals


*Source: NSE & BSE
ADTV (Shares): Average Daily Traded Volume
ADTV (INR Cr): Average Daily Traded Value



2

Company at a Glance

Our Journey


1968
Established Jet Chemicals Private Limited with Shahad facility (Unit I)
1970
Began manufacturing high-intensity sweeteners - saccharin and its salts
2000
Entered the X-ray contrast media sector, with a basic building block (5- NIPA)
2002
Commenced manufacturing of pharma intermediates and API
2003
Established Blue Circle Organics Private Limited (at Unit-II, Ambernath facility)
2017
Commenced semi-automated manufacturing block for contrast media intermediate business
2019
Received USFDA Establishment Inspection Report of Blue Circle Organics Private Limited for Unit II
Merger between Blue Circle Organics and Jet Chemicals to form Blue Jet Healthcare Private Limited
2020
Acquisition of brownfield site in Mahad (Unit III) on a leasehold basis
2021
Acquisition of greenfield site in Ambernath (Unit IV) on a leasehold basis
2025
Supply of Pharmaceutical Intermediate to an innovator
Company successfully commissioned Plant 6 at Ambernath
2026
Acquisition of land near Vizag and groundbreaking of the project
Launch of QIP. Raised ₹8,000 mn

Who we are

A **specialty pharmaceutical** and

healthcare ingredient and **intermediate**

company, offering **niche products** with

an approach of **“Collaboration,**

Development, Manufacturing” to

CDMO business.



Blue Jet Healthcare at a glance

Key metrics

51[1]
Commercialized product portfolio (FY26)

1,175.60 KL
reaction capacity across 3 facilities (FY26)

₹ 9,473.2 mn
Revenue (FY26) (13.7% FY21-26 CAGR)

₹ 2,940.99 mn
EBITDA (FY26) (31.0% margin)

24.9%
ROCE (FY26)

19.9%
ROE (FY26)

3.75x
Fixed Asset Turnover (FY26)

₹ 3,619 mn
Cash and Cash Equivalents + Treasury Investments (as of 31st March 2026)

Business Overview

Three product categories: **Contrast Media Intermediates, High Intensity Sweeteners, and Pharma Intermediates & Active Pharmaceutical Ingredients ("API")**

Specialised chemistry capabilities; with dedicated R&D laboratories




Long-standing relationships and **multi-year contracts** with multi-national customers

Manufacturing facilities with regulatory accreditations

1. Includes 19, 4, and 28 commercialized products for contrast media, high intensity sweeteners, and pharma intermediates and APIs respectively

Source: Company Information

Overview of our Product Categories

	Contrast Media Intermediates	High Intensity Sweeteners	Pharma Intermediates & APIs
Overview	■ Contrast media are agents used in medical imaging to enhance the visibility of body tissues ■ Company supplies critical starting intermediate and several advanced intermediates	■ High-intensity sweetener business involves development, manufacture and marketing of saccharin and its salts	■ Collaboration with innovator pharmaceutical companies and multi-national generic companies ■ Provides intermediates that serve as pharmaceutical building blocks for APIs in chronic therapeutic areas
End uses	 *X-ray & CT Scan*  *MRI Scan*	■ Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds	■ Chronic therapeutic areas such as cardiovascular system ("CVS"), central nervous system ("CNS"), oncology etc
# of commercialized products (FY26)	**19**	**4**	**28**
Revenue contribution (FY26)	 52.50%	 13.90%	 31.60%
Client relationships	■ Top 4 players accounts for **~75%** global market share[1] ■ **4–27** years of relationship with the **3 of the largest manufacturers .**	■ **Offers high-intensity sweeteners to over 300** customers globally ■ **Marquee customers – in FMCG and Agro chemical Space**	■ Markets predominantly in **regulated markets** ■ Over **56** customers globally of which **40** in India

Note: [1] In each of MAT June 2019, 2020, 2021, 2022 and 2023
Source: Company information, IQVIA report dated October 9, 2023 ("Industry Report")



3

Contrast Media Intermediates

Overview of Contrast Media and its growth drivers

What is contrast media?

- Chemical agents that **enhances the contrast of an imaging modality** in diagnostic imaging, thereby **aiding diagnosis of diseases**
- Once inside the human body, selectively and temporarily taken up by different body tissues
- **Enhance the images, leading to better visualizations of the tissues and organs**

Types of contrast media

- **X-ray / Computed Tomography (CT) contrast agents:** Iodine-based contrast media agents
- **Magnetic Resonance Imaging (MRI) contrast agents:** Gadolinium-based agents
- **Ultrasound (USG) agents:** Stabilized microbubble-based contrast media agents

Growth drivers for contrast media

Growing population and changing demographics
(65 yrs.+) estimated to increase from 6.9% of the total world population in 2000 to 10.4% by 2025[1]

Growing prevalence of lifestyle diseases
Such as diabetes, physical inactivity, obesity, etc.

Increased convenience
Through online booking and reporting

Rising healthcare expenditure
Global health expenditure grew at 3.9% CAGR from 2000–17


Focus on early diagnostics
Driven by advancement in diagnostic technologies and growing public awareness

Increasing demand for preventive healthcare
Driven by increased awareness and rising curative costs


Note: [1] World Bank national account data
Source: Industry Report

The global Contrast Media industry is highly concentrated


Global Medical Imaging Market (USD Bn)



Global Contrast Media Formulation Market Revenue (USD Bn)




Revenue Share of Contrast Agent type, 2024




- Collectively **hold ~75% of the global sales of** contrast media formulations[1]
- **Highly concentrated** and **dominated by multi-national corporations**
- Either **forward integrated** (have equipment manufacturing) or **long-standing relationships with manufacturers**

Global Contrast Media Formulations Market, Market Share of Top Companies, 2024



Global Contrast Media Intermediates Market Revenue (USD Mn)



1. June 2019, 2020, 2021, 2022 and 2023

Source: F&S Report

High entry barriers for key intermediates' vendors

Characteristics of the Contrast Media market

- **Strict internal standards for product impurity / features profile**
- **Stickiness of relationship**
- **Long-term supply contracts**


Blue Jet's positioning

- ✓ More than **two decades of experience**
- ✓ **75%+ of exports** of a selected contrast media intermediate **(5-Amino-N,N'-bis (2,3-dihydroxypropyl) isophthalamide)** from India[1]
- ✓ Strategically **focused on complex chemistry** categories

- ✓ Regularly supplying **key starting intermediate** as the building block
- ✓ Several **functionally critical advanced intermediates**
- ✓ **4 to 27** years with 3 of the largest contrast media manufacturers in the world, directly

- ✓ **Medium to long term supply contracts** with customers
- ✓ **~70% of total sales** backed by **contracted** sales volumes[2]
- ✓ **Products qualified, approved and validated**

Contrast Media Intermediate product category performance



Source: Company information

Note: [1] In each of the Financial Years 2020, 2021 and 2022; 2 For Financial Years 2021, 2022, 2023 and three months ended 1Q 2023
Source: Industry Report

Continue to forward integrate into more advanced intermediates for Contrast Media

Strong product development and process **optimization capabilities** underpinned by **in-house R&D capabilities**

Focus on molecules with **customer interest** and **strategy** in either **outsourcing or alternate sourcing** the next stage of advanced intermediates

Key starting intermediate as building block in 2000 to **19 additional advanced intermediates** as of FY26

Further **improving chemistry** capabilities in close **synergy** with our customers (**4 to 27** years with 3 of top 4 players directly)

Key benefits

Capture **larger wallet share** with existing customers

Higher realization and **profitability** per unit

Potential of **moving up the value chain**



4

High Intensity Sweeteners

Blue Jet’s positioning in High Intensity Sweetener

Blue Jet's positioning

Products

- Adherence **to strict internal standards** to ensure **consistency in quality, performance, taste, and impurity profile**
- **Multiple products** and **applications** enabling to cater a **diverse customer base**


Compliance, GMP, supply chain reliability

- **Have received US-FDA inspection report**
- Semi-automated manufacturing facility
- **Strong product development and process optimization capabilities**

Customers

- Offers high-intensity sweeteners to over **300 customers globally**
- Focus on **marquee customers** across various sub-sectors
  - Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds


High Intensity Sweeteners product category performance




Sources: Company information

Global High Intensity Sweeteners Market

Global Artificial Sweeetener Market Revenue (USD Mn)




Global High-intensity Sweetneer Market, Revenue share by segments, 2024




Global Sucralose Market Revenue (USD Mn)

CAGR, 2019-2024 - 5.2%
CAGR, 2024-2029F - 5.7%



Global Saccharin Market Revenue (USD Mn)

CAGR, 2019-2024 - 7.9%
CAGR, 2024-2029F - 8.5%



Source: Industry Report



5 Pharma Intermediates & API

Trends and features of the Pharma Intermediates and APIs Product Category

Key trends in Pharma Intermediates and CDMO market

Increased propensity to outsource manufacturing of intermediates & APIs

- **Enables asset light model** and ability to focus on development of **novel products for venture capital backed start-ups**
- **Provides cost advantages** and **supply chain efficiencies**

De-risking dependence on China by global API and formulations players

- Concerns around specific APIs made in China, accentuated with Covid-19
- China **implemented stricter regulations** and witnessed rising wage costs

Self sufficiency with import substitution

- Government initiatives such as **PLI schemes** and **bulk drug parks**
- Growth driven by **proven skills, educational systems, supply chain reliability, and IP protection**

The growth in the global pharmaceuticals market

- Launch of novel therapies (including biologics and personalized therapies)
- Expansion of existing therapies in several geographies
- Growing demand for generic medicines

Revenue and capacity utilization predictability for the CDMO

- Customers prefers close partnerships with CDMO driven by
  - Confidentiality of the projects
  - Novelty of the underlying chemistry and need for custom-development

Features of a typical arrangement to supply of intermediates to innovators of NCEs

Higher realizations per unit sold

- Key criteria for selection of CDMO include track record in the chemistry and similar therapy areas
- Competitive cost is not the most important consideration

Source: Industry Report

Overview of Blue Jet's Pharma Intermediates and APIs Product Category

Salient features

- Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity sweetener business
- Key focus areas include high-value pharma intermediates and APIs
  - In chronic therapeutic areas
  - Import substitution market
- Benefit from collaboration with innovator companies because typical technology transfer reduces the development risk


Client profile

- Innovator pharmaceutical companies and multi-national generic pharmaceutical
- Over 40 customers in India, and 16 globally across Europe, North America, South America, and Asia

Therapeutic areas


- Cardiovascular system ("CVS")
- Oncology
- Central nervous system ("CNS")

Pharma Intermediate and APIs product category performance




CDMO Potential in API for Indian Players


Global CDMO Market by Modality (USD Bn)




Global CDMO Market Revenue (USD Bn)



Global API CDMO Market by Innovation Type (USD Bn)




Indian CDMO Market Revenue (USD Bn)



Source: F&S Report

Cost of R&D and Manufacturing - Comparison of USA versus other regions, 2024



Note: Relative numbers indexed against the USA, based on Industry KOL estimates

Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category

Focus on three niche areas in providing CDMO services



Investigational new drugs and new chemical entities (NCEs)

Develop advanced intermediates for NCEs under trials for US-FDA approvals



Drugs that are still under patent and not genericized

Offering advanced intermediates to innovators for four active pharmaceutical ingredients (APIs) which are still under patent

- Including two APIs in the oncology sector, one API in the cardiovascular system category and one API in the central nervous system category



Genericized drugs that are still niche

Offering multiple advanced intermediates to a number of large generics companies for chronic illness therapies

Blue Jet's positioning



Leverage long-standing relationships with innovator companies



Process research, analytical research and chemistry capabilities



Continuous focus on product quality



6

R&D Capabilities

Our R&D framework

R&D capabilities across

Process research

Portfolio evaluation → **Process development** → **Process scale-up and validation** → **Regulatory filings and approvals**

Analytical research

- Literature search
- Method development and optimization
- Characterization of impurities and standards
- Method validation
- Non-carry over studies
- Stability/hold-time studies

Chemistry research

- Polymorphism screening and optimization
- Pharmaceutical salt screening and optimization
- Cryogenic reactions
- High pressure reactions
- High temperature reactions
- Asymmetric hydrogenation
- Enzymatic transformations
- Particle size distribution studies


Innovative and complex processes

- Catalytic hydrogenation
- Iodination
- Bromination
- Chlorination
- Diazotization
- Esterification
- Hoffman re-arrangement

Strengthening R&D Capabilities with Our New Hyderabad Facility








Sustainability

Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint

Invested in windmills with installed capacity of 3.3MW

Created carbon sinks through tree plantations

Focus on enhancing energy efficiency

Effluent treatment plants with modern standards of flocculation, clarification and aeration

Minimizing solvents and using recycled solvents and water





7

Growth Strategy

Our strategies





8

Management and Board of Directors

Experienced and visionary management team backed by independent - Board of Directors

Management team



Akshay Bansarilal Arora
Executive Chairman

- Has more than three decades of experience with the Company
- Holds bachelor's and master's degrees in science from University of Mumbai



Shiven Akshay Arora
Managing Director

- Has more than six years of experience with the Company
- Holds a bachelor's degree in business from Bond University, Gold Coast, Australia



Naresh Suryakant Shah
Executive Director, Head – Marketing

- Has more than three decades of experience in marketing
- Currently also associated as a director of BC Bio Sciences
- Holds a diploma in Chemical Engineering from the Khopoli Polytechnic College, Raigad



Ganesh Karuppannan
Chief Financial Officer

- Previously worked with Philips Electronics, Dr. Reddy's Laboratories, Granules as CFO
- Associate member of Institute of Chartered Accountants of India since 1988



Vimalendu Kumar Singh (V.K. Singh)
Chief Operating Officer

- Previously worked with Strides Pharma, Emcure Pharmaceuticals, RPG Life Sciences, and Ranbaxy Laboratories
- Has a bachelor's degree in chemical engineering from IIT Kanpur and a master's programme from IIFT, New Delhi



Chandrashekar Parenky
President – Research and Development

- Previously worked at Amoli Organics and Kores (India) as CEO
- Holds a doctorate of philosophy in science from the University of Bombay and a master's degree from Birla Institute of Technology & Science

Experienced and visionary management team backed by independent Board of Directors (cont'd)

Management team (cont'd)



Popat B Kedar
Executive Director

- Holds a Bachelor's and Master's degree in Science, specializing in Inorganic Chemistry from Shivaji University, Kolhapur.
- Has over 34 years of experience as a Plant Manager, previously working with Infotech Pharma Pvt. Ltd., Godavari Drugs Pvt. Ltd., and Sara Research Centre.
- Associated with the company since July 2005 and served as a Director at Blue Jet Healthcare Limited from December 31, 2020, to February 1, 2022.



Sweta Poddar
Company Secretary and Compliance Officer

- Has experience of over a decade as a company secretary
- Associated with Chinar Chemicals Private Ltd. and Aarey Drugs and Pharmaceuticals Ltd.
- Holds a bachelors' degree in commerce from the University of Calcutta

Independent board of directors



Girish Paman Vanvari
Independent Director

- Founder and Partner of Transaction Square LLP and Valuation Square LLP . He is the member of Institute of Chartered accountants of India.
- Has experience in tax, regulatory, and business advisory functions
- Holds a bachelor's degree in commerce from Shri Narsee Monjee College of Commerce and Economics
- Other Directorships held: Tarsons Products Ltd , Aurbindo Pharma Ltd , Himadri Specilaity Chemical Ltd, Kolte Patil Developers Ltd



Preeti Gautam Mehta
Independent Director

- Practicing advocate & solicitor and a senior partner of Kanga & Co
- Over 30 years of experience in corporate laws, foreign investments, M&A & PE investments, banking, franchising, and hospitality
- Other Directorships held: Sumitomo Chemicals Ltd, Prpten - E Gov Technlogies Ltd, JCB India Ltd



Divya Sameer Momaya
Independent Director

- Holds a bachelor's degree in commerce from the University of Pune
- Partner of D. S. Momaya & Co. LLP and first director of MMB Advisors Private Limited
- Previously worked with BSE Limited and BSEL Infrastructure Realty Limited
- Other Directorships held: GTPL Hathway Ltd, Motilal Oswal Finacial Services Ltd, Motial Oswal Home Finance ltd



Priyanka Yadav
Independent Director

- Ms. Priyanka Yadav, a Fellow Member of ICSI, holds bachelor's, master's, and law degrees from the University of Mumbai.
- She leads Priyanka Yadav & Associates with 6+ years of experience in corporate laws, NCLT matters, and compliance.
- An expert in listing compliance, IPOs, and corporate restructuring, she advises on governance and legal due diligence.

Thank you!

BLUE JET HEALTHCARE LIMITED

Registered Office
701,702, 7th Floor, Bhumiraj Costarica,
Sector 18, Sanpada, Navi Mumbai Thane
400705, Maharashtra, India

NSE: BLUEJET, **BSE:** 544009
ISIN: INE0KBH01020
Website: www.bluejethealthcare.com

INVESTOR RELATIONS AT

Blue Jet Healthcare Limited
Sanjay Sinha, Deputy Chief Financial Officer
sanjay.sinha@bluejethealthcare.com

EY

Kunal Bhoite
kunal.bhoite@in.ey.com

Advait Bhadekar
advait.bhadekar@in.ey.com